PreDxion Bio
PreDxion Bio, based in South San Francisco, specializes in diagnostic healthcare technologies, including a rapid saliva-based antigen test for SARS-CoV-2 and a cytokine detection platform for monitoring critically-ill patients.
About PreDxion Bio
PreDxion Bio is a healthcare diagnostics company based in South San Francisco, CA, USA. With a dedicated team of 6 members, the company operates across regions such as the United States, America/Canada, and partly remote locations. PreDxion Bio is recognized for its innovative diagnostic technologies, including rapid monitoring of cytokine and biomarker levels in critically-ill patients and scalable solutions for widespread testing.
Innovative SARS-CoV-2 Testing Solution
PreDxion Bio offers a rapid saliva-based antigen test designed specifically for the detection of SARS-CoV-2 S-protein in asymptomatic and presymptomatic patients. This cutting-edge technology can be scaled to produce tens of millions of tests per day utilizing semiconductor fab processes, addressing urgent needs for widespread COVID-19 testing.
Core Technology and Applications
The company’s core technology is a rapid, near real-time cytokine and biomarker detection platform that monitors immune responses in critically-ill patients. Developed from a novel sensor platform spun out of the University of Michigan, this technology plays a crucial role in guiding precision medicine approaches, particularly in critical care settings. PreDxion Bio's platform is pivotal in detecting and analyzing immune responses for improved patient outcomes.
FDA Breakthrough Device Designation
PreDxion Bio's advancements in healthcare have been recognized with the FDA Breakthrough Device designation. This accolade underscores the significance of their technology in providing critical, timely insights into the immune responses of patients, particularly those undergoing substantial therapies or facing severe illnesses.
Partnerships with Pharmaceutical Companies
PreDxion Bio has established collaborative partnerships with top pharmaceutical companies to monitor immune responses in patients undergoing CAR-T therapy. These partnerships aim to predict the development of cytokine release syndrome and neurological adverse events, enhancing patient care and therapy effectiveness through early detection and intervention.